The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Crombez Eric since 2024.
This trader's CIK number is 1653052.
At the time of last reporting, Crombez Eric was the EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc.. (stock ticker symbol RARE).
Also see all insider trading activities at Ultragenyx Pharmaceutical Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | RARE | 0 | $0 | 7,029 | $160,261 | 0 | $0 |
| 2025 | RARE | 0 | $0 | 9,707 | $405,484 | 0 | $0 |
| 2024 | RARE | 0 | $0 | 1,734 | $88,271 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | ABEO | 0 | $0 | 16,284 | $82,901 | 0 | $0 |
| 2025 | ABEO | 0 | $0 | 4,718 | $32,681 | 0 | $0 |
1. Ultragenyx Pharmaceutical Inc. (RARE)
2. Abeona Therapeutics Inc. (ABEO)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-03-02 | RARE | Sale | 7,029 | 22.80 | 160,261 |
| 2025-05-05 | RARE | Sale | 520 | 39.24 | 20,404 |
| 2025-04-21 | RARE | Sale | 242 | 35.11 | 8,496 |
| 2025-03-03 | RARE | Sale | 8,945 | 42.10 | 376,584 |
| 2024-05-02 | RARE | Sale | 354 | 43.66 | 15,455 |
| 2024-04-18 | RARE | Sale | 142 | 44.10 | 6,262 |
| 2024-03-01 | RARE | Sale | 1,238 | 53.76 | 66,554 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-02-02 | ABEO | Sale | 16,284 | 5.09 | 82,901 |
| 2025-08-14 | ABEO | Sale | 4,718 | 6.93 | 32,681 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Crombez Eric (EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.